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Gene expression proﬁleLaryngeal squamous cell carcinoma (LSCC) is one of themost commonmalignancies of the head and neck tumors
Zhang et al., 2013 [1]). Previous studies have associated its occurrence with social activities, such as tobacco and
alcohol consumption (Hashibe et al., 2007a [2]; Hashibe et al., 2007b [3]; Shangina et al., 2006 [4]). Here, we per-
formed a genome-wide gene expression proﬁling in thirty-one patients positively diagnosed for LSCC, in order to
investigate new targets involved in tumorigenesis.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).go Microarray chips
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. This is an open access article under2. Experimental design, materials and methods
2.1. Study population and clinical data
All the samples were collected from patients undergoing surgi-
cal ablation of larynx squamous cell carcinoma at the Head and
Neck Surgery Division of the Department of Ophthalmology, Oto-
rhinolaryngology and Head & Neck of Ribeirao Preto Medical
School, USP (Brazil). Inclusion criteria were: histopathological di-
agnosis of LSCC, elective surgeries for LSCC in patients without pre-
vious treatments and patients' allowance to donate part of their
tumor for genetic studies. Exclusion criteria were: doubtful diag-
nosis of LSCC, unavailable post-surgical follow-up, patients with-
out complete clinical data or signed agreement for collection of
samples.
A total of twenty nine LSCC tumor samples and thirteen adja-
cent non-neoplastic tissues proceed for the transcriptome analysis.
Clinical information and TNM staging classiﬁcation of the LSCC pa-
tients can be found in Table 1 and Supplemental Table 1. In our
study most of the patients were male (96.8%), all of them were
smokers and alcoholic, including both current and former. Thirty
ﬁve percent of the tumors were originated from glottis, followed
by larynx (29.0%) and supraglottis (22.6%). Patients were further
classiﬁed according to the TNM system: 48.4% of the patientsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Boxplot shows the percent of the coefﬁcient of variation for non-control probes to
each array. The asterisk represents the technical replicate array.
Table 1
Clinical information of LSCC patients.
Characteristics Staging Total (n= 31)
Early (n= 15) Late (n= 16)
Mean ages
Year (min–max) 60 (40–78) 62.2 (49–83) 61.1
Gender
Male 14 (93.3%) 16 (100%) 30 (96.8%)
Female 1 (7.7%) 0 (0%) 1 (3.2%)
Smoking (%)
Smoker 11 (73.3%) 6 (37.5%) 17 (54.8%)
Former smoker 4 (26.7%) 10 (62.5%) 14 (45.2%)
Non-smoker 0 (0.0%) 0 (0.0%) 0 (0.0%)
Alcoholism (%)
Alcoholic 10 (66.7%) 7 (43.75%) 17 (54.8%)
Former alcoholic 5 (33.3%) 9 (56.25%) 14 (45.2%)
Non-alcoholic 0 (0.0%) 0 (0.0%) 0 (0.0%)
Tumor site
Glottis 6 (40%0) 5 (31.3%) 11 (35.5%)
Larynx 3 (20.0%) 6 (37.5%) 9 (29.0%)
Supraglottis 3 (20.0%) 4 (25.0%) 7 (22.6%)
Subglottis & oropharynx 1 (6.7%) 0 (0%) 1 (3.2%)
Glottis & supraglottis 0 (0%) 1 (6.3%) 1 (3.2%)
Laryngopharynx 1 (6.7%) 0 (0%) 1 (3.2%)
Epiglottis 1 (6.7%) 0 (0%) 1 (3.2%)
Tumor relapse 4 (26.7%) 4 (25.0%) 8 (25.8%)
Metastasis 1 (6.7%) 2 (12.5%) 3 (9.7%)
Cured?
Yes 7 (46.7%) 9 (56.3%) 16 (51.6%)
No 8 (53.3%) 7 (43.8%) 15 (48.4%)
Patient status
Alive 9 (60.0%) 10 (62.5%) 19 (61.3%)
Dead 6 (40.0%) 6 (37.5%) 12 (38.7%)
Follow-up
Month average 41 46 44
Fig. 2. Scatter plot representing the principal component analysis from expression arrays.
The dots are colored by tumor (red) and adjacent non-neoplasic tissue samples (blue).
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showed similar proportions of tumor relapse, cured and dead pa-
tients. This study was approved by the Ethics Committee of
Ribeirao Preto Medical School, University of Sao Paulo (USP)
(Proc. No. 9371/2003) and signed informed consent was obtained
from all patients.
2.2. Microarray experiments
After LSCC histopathological conﬁrmation and microdissection of
the tumors from their non-neoplastic adjacent tissue, the samples
were store in liquid nitrogen. Total RNA was extracted with TRIzol
(Life Technologies, USA). After extraction, the RNA was puriﬁed
with RNeasy Kit (Qiagen, USA) and quantiﬁed with Nanodrop spec-
trophotometer (Thermo Scientiﬁc, USA). Its quality was evaluated
by 1.5% agarose gel electrophoresis (28S and 18S ribosomal RNA
detection).
For the microarray analysis it was used the Whole Human Ge-
nome Oligo Microarray kit 4 × 44K (Agilent, G4112F, USA). cDNA
was hybridized to the microarray chip in the Fluidics Station 450
system (Affymetrix, USA), using the Quick Amp Labeling one-color
kit (Agilent, USA). As an internal mRNA control, the One Color
RNA Spike-In Kit was used (Agilent, USA). The arrays were scanned
by the Agilent Scanner G2505C. Agilent Feature Extraction software
(version 9.5.3.1) was used to analyze acquired array images.
2.3. Quality control and signal pre-processing
Plain text ﬁles were loaded and processed into R with the
bioconductor package Agi4 × 44Pre-Process [5]. The annotation
package hgug4112a.db [6] was used to assign gene information to
each probe. The CV.rep.probes functionwas used to estimate the per-
cent of coefﬁcient of variation (% CV) for replicated non-controlprobes, inferring the reproducibility of the arrays (Fig. 1). The
gProcessedSignal and the gBGUsed values of each array were loaded
as foreground and background signals, respectively into an RGList
object. Next, those arrays were renamed according to each sample
clinical information. The following ﬂags were used to ﬁlter probes:
Control, Well Above BG, Is Found, Well Above NEG CTRLS, Is Saturat-
ed, Population Outlier, and Non Uniform Outlier. Additionally probe
signals with at least 90% of good features in an experimental condi-
tion were selected. Logarithmic transformation of base 2 was applied
for high quality probes. Quality control was accessed with package
arrayQualityMetrics [7]. Outlier detection did not identify experi-
mental problems. It was performed by looking for arrays (a and b),
which the sum (S) of the distances (d) to all other arrays, Sa = Σb
dab was exceptionally large; calculating the Kolmogorov–Smirnov
statistic (Ka) between each array and the pooled data distribution;
Fig. 3. Volcano plot based on log2 fold-change against−log10 (p-value) showing genes overexpressed in tumor samples (green dots) and adjacent non-neoplasic tissue samples (red dots).
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A and M for each array (M = log2(I1) − log2(I2); A = 1/2
(log2(I1) + log2(I2)), where I1 is the intensity of the array studied,
and I2 is the intensity of a “pseudo”-array that consists of the median
across arrays).
2.4. Normalization
Stagewise normalization is recommended when data include tech-
nical and biological replicates producing a better median chip [8]. Nor-
malization stepswere donewith the R bioconductor package limma [9].
Technical replicates were normalized between arrays using the smooth
function “cyclicloess”. Then, quantile normalization methods were ap-
plied, within groups and subsequently between all arrays. Each set of
replicated non-control probes has been collapsed into a single value
computed as the median of the probes intensities belonging to the
same set.
2.5. Differentially expressed genes and pathways analysis
Principal component analysis (PCA) was applied to classify samples
by tumor and adjacent non-neoplastic tissue as demonstrated on Fig. 2.
We compared the gene expression between tumor and adjacent non-
neoplastic tissue using a non-paired-T test analysis. False discovery
rate (FDR) adjusted p-value b 1e−07 and fold change (FC) N 10 were
accepted to consider genes to be differentially expressed, identifying a
total of 81 probes above this cut-off (Fig. 3). Then we investigated the
biological process of upregulated and downregulated genes in tumor
compared to normal sampleswithWeb-based Gene Set Analysis Toolkit
(WebGestalt) [10]. P-value was calculated using hypergeometric
distribution and FDR as multiple hypothesis test correction method.The cut-off was set at b0.05. Tissue morphogenesis (GO: 0009888)
and differentiation (GO: 0032332) are the main biological process in
upregulated genes while cytokines and growth factor genes are highly
expressed in adjacent non-neoplastic patients, suggesting a role on
LSCC tumorigenesis.
3. Discussion
We describe detailed technical methods to reproduce the analysis
of Whole Human Genome Oligo Microarray kit (Agilent, G4112F,
USA) from twenty-nine LSCC tumor samples and thirteen adjacent
non-neoplastic tissues. LSCC is the second most common malignan-
cies of the head and neck tumors [1], and this high frequency may
be associated with the lifestyle of patients [2–4]. The high quality
gene expression data are concordant with important clinical param-
eters, demonstrating the relevant expression proﬁle signature of dif-
ferentially expressed genes. This data can contribute to future
investigations examining molecular changes that promote LSCC
tumorigenesis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2015.04.024.
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